Aliskiren: The next innovation in renin-angiotensin-aldosterone system blockade

Aging Health

Volumn 5, Issue 3, 2009, Pages 269-279

  Duprez, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Aliskiren; Diabetes; Diabetic nephropathy; Direct renin inhibitor; Heart failure; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; VALSARTAN;

ACUTE HEART FAILURE; ADD ON THERAPY; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; COUGHING; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MONOTHERAPY; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC HYPERTENSION; TREATMENT RESPONSE;

EID: 70249111167     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.09.21     Document Type: Article

References (52)

1. Gibbons RJ, Jones DW, Gardner TJ, Goldstein LB, Moller JH, Yancy CW: The American Heart Association's 2008 statement of principles for healthcare reform. Circulation 118, 2209-2218 (2008).
2. Rosamond W, Flegal K, Furie K et al.: Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, E25-E146 (2008).
3. Bakris G, Hill M, Mancia G et al.: Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J. Hum. Hypertens. 22, 63-70 (2008).
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
5. Duprez DA: Role of the renin - angiotensin - aldosterone system in vascular remodeling and inflammation: a clinical review. J. Hypertension 24, 983-991 (2006).
6. Fisher ND, Hollenberg NK: Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. 16, 592-599 (2005).
7. Azizi M: Renin inhibition. Curr. Opin. Nephrol. Hypertens. 15, 505-510 (2006).
8. Wood JM, Maibaum J, Rahuel J et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698-705 (2003).
9. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF: Plasma renin and the antihyperten effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int. J. Clin. Pract. 61, 1461-1468 (2007).
10. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet. 47, 515-531 (2008).
11. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R: Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol. 62, 690-698 (2006).
12. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin Dieterich H: Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type 2 diabetes mellitus. Clin. Pharmacokinet. 45, 1125-1134 (2006).
13. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. 24, 243-256 (2006).
14. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32, 387-392 (1998).
15. Mooser V, Nussberger J, Juillerat L et al.: Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 15, 276-282 (1990).
16. Burnier M, Brunner HR: Angiotensin II receptof antagonists. Lancet 355, 637-645 (2000).
17. Rousseau MF, Gurne O, Duprez D et al.: Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J. Am. Coll. Cardiol. 40, 1596-1601 (2002).
18. Schjoedt KJ, Rossing K, Juhl TR et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536-542 (2006).
19. van de Wal RM, Plokker HW, Lok DJ et al.: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int. J. Cardiol. 106, 367-372 (2006).
20. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1-E8 (2002).
21. Stanton A, Jensen C, Nussberger J, O'Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42, 1137-1143 (2003).
22. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111, 1012-1018 (2005).
23. Villamil A, Chrysant SG, D Calhoun et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 25, 217-226 (2007).
24. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A: Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J. Am. Soc. Hypertens. 1, 264-277 (2007).
25. Kushiro T, Itakura H, Ato Y, Gotou H, Terao S, Keefe DL: Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens. Res. 29, 997-1005 (2006).
26. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. 49, 1157-1163 (2007).
27. Schmieder RE, Philipp T, Guerediaga J et al.: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 119, 417-425 (2009).
28. Andersen K, Weinberger MH, Egan B et al.: Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J. Hypertens. 26, 589-599 (2008).
29. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H: A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J. Hum. Hypertens. 21, 780-787 (2007).
30. Mancia G, De Backer G, Dominiczak A et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28, 1462-1536 (2007).
31. Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL: Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens. (Greenwich) 9, 742-750 (2007).
32. Uresin Y, Taylor AA, Kilo C et al.: Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 8, 190-198 (2007).
33. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221-229 (2007).
34. Latini R, Masson S, Anand I et al.: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur. Heart J. 25, 292-299 (2004).
35. Daniels LB, Maisel AS: Nitriuretic peptides. J. Am. Coll. Cardiol. 50, 2357-2368 (2007).
36. McMurray JJ, Pitt B, Latini R et al.: Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
37. Seed A, Gardner R, McMurray J et al.: Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure, Eur. J. Heart Fail. (2007).
38. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
39. Persson F, Rossing P, Schjoedt KJ et al.: Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in Type 2 diabetes. Kidney Int. 73, 1419-1425 (2008).
40. Solomon SD, Appelbaum E, Manning WJ et al.: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119, 530-537 (2009).
41. Vaidyanathan S, Reynolds C, Yeh CM et al.: Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J. Clin. Pharmacol. 47, 453-460 (2007).
42. Verdecchia P, Calvo C, Mockel V, Keeling L, Satlin A: Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 16, 381-391 (2007).
43. Duprez D, Davis P, Botha J: The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients greater than 65 years of age with systolic hypertension (late breaker presentation). Presented at: The American Heart Association Scientific Sessions 2008. New Orleans, LA, USA, 8-12 November 2008.
44. Dieterle W, Corynen S, Mann J: Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 58, 433-436 (2004).
45. Vaidyanathan S, Valencia J, Kemp C et al.: Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract. 60, 1343-1356 (2006).
46. Vaidyanathan S, Camenisch G, Schuetz H et al.: Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol. 48, 1323-1338 (2008).
47. Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK: Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117, 3199-3205 (2008).
48. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002).
49. Krop M, Garrelds IM, de Bruin RJ et al.: Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 52, 1076-1083 (2008).
50. Stankovic AR, Fisher ND, Hollenberg NK: Prorenin and angiotensin-dependent renal vasoconstriction in Type 1 and Type 2 diabetes. J. Am. Soc. Nephrol. 17, 3293-3299 (2006).
51. Duprez D, Davis P, Botha J: The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients greater than 65 years of age with systolic hypertension (late breaker presentation). Circulation 118, S886-S887 (2008).
52. Parving HH, Brenner BM, McMurray JJ et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24(5), 1663-1671 (2009).